- Datum03.11.2026
- Uhrzeit12:00 - 13:00 Uhr
- Veranstalter
stock3
Roche Holding AG Chart inkl. Chartanalyse

Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen

Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| BX Swiss | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Wertentwicklung (BX Swiss)
Passender Service zu Roche Holding AG
Webinar zu Roche Holding AG
Kursinformationen (BX Swiss)
- Tagestief / Hoch (Fr)-
- 52W-Tief / Hoch (Fr)258,604-391,608
- Jahrestief / Hoch (Fr)301,934-391,608
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Roche Holding AG
Termine von Roche Holding AG
- Feb4Roche Holding AGQ4 2026 Earnings Release
- Jul29Roche Holding AGQ2 2027 Earnings Release
- Feb3Roche Holding AGQ4 2027 Earnings Release
Beschreibung
Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. The company's reach extends across key markets like Switzerland, Germany, and the United States, in addition to its broader international footprint. Its extensive pharmaceutical division develops and offers treatments for a diverse range of conditions. These therapeutic areas encompass critical fields such as oncology (cancer), neuroscience, infectious diseases, immunology, hemophilia, ophthalmology (eye care), dermatology (skin conditions), respiratory illnesses, anemia, inflammatory and autoimmune disorders, and transplantation. Beyond medicinal products, Roche is also a prominent supplier of in vitro diagnostic tests. These tests are vital for identifying numerous diseases, including various cancers, cardiovascular conditions, diabetes, COVID-19, hepatitis, and human papillomavirus (HPV). Complementing its testing services, the company provides the essential diagnostic instruments and chemical reagents necessary for these procedures. Demonstrating its commitment to innovation, Roche has established a research partnership with Synlogic, Inc. This collaboration aims to discover a novel synthetic biotic designed specifically for the treatment of inflammatory bowel disease (IBD). Tracing its origins back to its founding in 1896, Roche Holding AG is headquartered in Basel, Switzerland.
